Antithrombin III Activity and Concentration in Diabetes Mellitus

G M Patrassi; R Picchinenna; R Vettor; G Cappellato; D Coccarielli; A Girolami

doi:10.1055/s-0038-1657862

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1985; 54(02): 415-417
DOI: 10.1055/s-0038-1657862

Original Article

Schattauer GmbH Stuttgart

Antithrombin III Activity and Concentration in Diabetes Mellitus

Authors

G M Patrassi

The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
R Picchinenna

The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
R Vettor

The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
G Cappellato

The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
D Coccarielli

The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
A Girolami

The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy

Abstract

PDF Download

Summary

Antithrombin III (AT III) levels have been reported to be low, normal, and high in diabetes mellitus. Furthermore, a dicrepancy between AT III activity and antigen concentration was reported. We have evaluated the behaviour of AT III activity and antigen level both in type 1 and type 2 diabetes, either in uncontrolled or in well controlled patients. AT III activity and antigen levels showed values similar to normal. No difference was seen between type 1 and type 2 diabetes. Similar results were observed in the group of well controlled diabetic patients. AT III activity and antigen did not correlate with blood glucose and glycosylated haemoglobin (HbA₁). No difference was observed between AT III activity and antigen levels in any group. Therefore the hypercoagulable state found in diabetes mellitus does not depend on AT III modifications. A discrepancy between AT III activity and antigen was not confirmed. A dysantithrombinaemia, explained on the basis of an inactivation of protein glycosylation in diabetes mellitus has not been confirmed.

Keywords

Antithrombin III activity and antigen - Glycosylated haemoglobin - Diabetes mellitus

PDF (1210 kb)

References

References
1 Rosemberg RO. Actions and interactions of antithrombin and heparin. N Eng J Med 1975; 292: 146-151
2 Filip DI, Eckstein JD, Veltkamp JJ. Hereditary antithrombin deficiency and thromboembolic disease. Am J Haematol 1976; 2: 343-349
3 Mackie M, Bennett B, Ogston D, Douglas AS. Familial thrombosis: inherited deficiency of antithrombin III. Br Med J 1978; 32: 136-138
4 Matsuo T, Ohki V, Kado S, Matsuo O. Familial antithrombin III deficiency in a Japanese family. Thromb Res 1979; 16: 815-823
5 Sas G, Blaskó G, Bánhegyi D, Jákó J, Pálos AC. Abnormal antithrombin III (Antithrombin III Budapest) as a cause of a familial thrombophilia. Thrombos Diathes Haemorrh 1974; 32: 105-115
6 Girolami A, Marafioti F, Rubertelli M, Vicarioto MA, Cappellato G, Mazzuccato M. Antithrombin III Trento. A “new” congenital AT III abnormality with a peculiar crossed-immunoelectrophoretic pattern in the absence of heparin. Acta Haematol 1984; 72: 73-82
7 Girolami A, Pengo V, Cappellato G, Vianello C, Procidano M, Cartei C. Antithrombin III Padua: a “new” congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Folia Haematol 1983; 110: 98-111
8 Girolami A, Fabris F, Cappellato G, Sainati L, Boeri G. Antithrombin III (AT III) Padua₂: A “new” congenital abnormality with defective heparin cofactor activities but no thrombotic disease. Blut 1983; 47: 93-103
9 Sas G, Köves A, Petö I, Domján G. On the inheritance of the abnormal antithrombin III (AT-III Budapest). Thromb Haemostas 1978; 39: 530-532
10 Jones RL, Peterson CM. Hematologic alterations in Diabetes mellitus. Am J Med 1981; 70: 339-352
11 Preston FE. Disorders of haemostasis in Diabetes mellitus. Ricerca Clin Lab 1982; 12: 425-438
12 Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lexis D, Bloom A. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983; 9: 254-259
13 Patrassi GM, Vettor R, Padovan D, Girolami A. Contact phase of blood coagulation in Diabetes mellitus. Europ J Clin Invest 1982; 12: 307-311
14 Banerjee RN, Sahni AL, Kumar V, Arya M. Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thrombos Diathes Haemorrh 1974; 31: 339-345
15 Ceriello A, Dello Russo P, Zuccotti C, Florio A, Nazzaro S, Pietrantuono C, Rosato GB. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report. Thromb Haemostas 1983; 50: 633-634
16 Gandolfo GM, De Angelis A, Torresi MV. Determination of antithrombin III activity by different methods in diabetic patients. Haemostasis 1980; 9: 15-19
17 Christe M, Fritschi J, Lämmle B, Tran TH, Marbert GA, Berger W, Duckert F. Fifteen coagulation and fibrinolysis parameters in Diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 138-143
18 Elder GE, Mayne EE, Daly JG, Kennedy AC, Hadden DR, Montgomery DAD, Weaver JA. Antithrombin III activity and other coagulation changes in proliferative diabetic retinopathy. Haemostasis 1980; 9: 288-296
19 Grignani G, Gamba G, Geroldi D, Pacchiarini L, Solerte B, Ferrari E, Ascari E. Enhanced antithrombin mechanisms in patients with maturity-onset diabetes mellitus without thromboembolic complications. Thromb Haemostas 1981; 46: 648-651
20 Gamba G, Grignani G, Montera V, Perotti G, Ragone L, Ascari E. Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic complications. Ricerca Clin Lab 1983; 13: 337-345
21 Borsey DQ, Prowse CV, Gray RS, Dawers J, James K, Elton RA. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol 1984; 37: 659-664
22 Abildgaard U, Lie M, Odegaard OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
23 Laurell CB. Quantitative estimation of proteins by electrophoresis of some human proteins. Anal Biochem 1966; 15: 45-52
24 Mancini G, Carbonara O, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-254
25 Werner W, Rey H, Wielinger H. Über die Eigenschaften eines neuen Chromogens für die Blutzuckerbestimmung nach der GOD/POD-Methode. Z Analyt Chem 1980; 252: 224-227
26 Trivelli LA, Ranne YHM, Lay HT. Haemoglobin components in patients with diabetes mellitus. N Eng J Med 1971; 284: 353-357
27 Corbella E, Miragliotta G, Maspery R, Villa S, Bini A, De Gaetano G, Chiumello G. Platelet aggregation and AT III levels in diabetic children. Haemostasis 1979; 8: 30-37
28 Bunn HF. Nonenzymatic glycosylation of protein: relevance to Diabetes. Am J Med 1981; 70: 325-330
29 Czech A, Taton J. Glycosylated Hemoglobin (HbA₁) as an indicator of therapy effects in different clinical types of diabetes. J Chron Dis 1983; 36: 803-810
30 Ceriello A, Curcio F, Dello Russo P, Giugliano D. Non-enzymatic glycosylation reduces antithrombin III activity. Thromb Haemostas 1984; 52: 363